Heron Therapeutics, Inc.

NasdaqCM:HRTX Stock Report

Market Cap: US$240.3m

Heron Therapeutics Dividends and Buybacks

Dividend criteria checks 0/6

Heron Therapeutics does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.3%

Buyback Yield

Total Shareholder Yield-0.3%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge

Nov 13
Why Investors Shouldn't Be Surprised By Heron Therapeutics, Inc.'s (NASDAQ:HRTX) 30% Share Price Plunge

Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%

Nov 13
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 30%

Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%

Aug 08
Investors Don't See Light At End Of Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Tunnel And Push Stock Down 32%

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

May 30
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too

Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

Apr 16

Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Mar 15
Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results

Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Feb 15
Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%

Dec 22
Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%

Heron wins FDA nod for post-operative agent to address nausea and vomiting

Sep 16

Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?

Aug 10
Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?

Heron Therapeutics Q2 2022 Earnings Preview

Aug 08

Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan

Jun 30

Heron Therapeutics: Cash Is A Problem Again

Mar 31

Heron Therapeutics: Changing Strategy After Disappointing Earnings

Mar 03

Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?

Jan 19
Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?

Heron Therapeutics: Looking For Signs Of The Bottom

Oct 07

Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?

Oct 03
Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if HRTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HRTX's dividend payments have been increasing.

Dividend Yield vs Market

Heron Therapeutics Dividend Yield vs Market
How does HRTX dividend yield compare to the market?
SegmentDividend Yield
Company (HRTX)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.5%
Industry Average (Biotechs)2.4%
Analyst forecast (HRTX) (up to 3 years)n/a

Notable Dividend: Unable to evaluate HRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate HRTX's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as HRTX has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 10:07
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Heron Therapeutics, Inc. is covered by 21 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Boran WangAegis Capital Corporation
Tazeen AhmadBofA Global Research
Jonathan AschoffBrean Capital